These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16847942)

  • 1. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage.
    Horstmann M; Schaefer T; Aguilar Y; Stenzl A; Sievert KD
    Neurourol Urodyn; 2006; 25(5):441-5. PubMed ID: 16847942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects.
    Amend B; Hennenlotter J; Schäfer T; Horstmann M; Stenzl A; Sievert KD
    Eur Urol; 2008 May; 53(5):1021-8. PubMed ID: 18243516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity.
    Reddy PP; Borgstein NG; Nijman RJ; Ellsworth PI
    J Pediatr Urol; 2008 Dec; 4(6):428-33. PubMed ID: 19013412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolterodine for overactive bladder: time to onset of action, preferred dosage, and 9-month follow-up.
    Atan A; Konety BR; Erickson JR; Yokoyama T; Kim DY; Chancellor MB
    Tech Urol; 1999 Jun; 5(2):67-70. PubMed ID: 10458657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
    Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
    BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
    Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
    Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of extended-release tolterodine for the treatment of neurogenic detrusor overactivity and/or low-compliance bladder.
    Watanabe M; Yamanishi T; Honda M; Sakakibara R; Uchiyama T; Yoshida K
    Int J Urol; 2010 Nov; 17(11):931-6. PubMed ID: 20969642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of extended-release and instant-release tolterodine in children with neural tube defects having cystometric abnormalities.
    Mahanta K; Medhi B; Kaur B; Narasimhan KL
    J Pediatr Urol; 2008 Apr; 4(2):118-23. PubMed ID: 18631906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity.
    Ethans KD; Nance PW; Bard RJ; Casey AR; Schryvers OI
    J Spinal Cord Med; 2004; 27(3):214-8. PubMed ID: 15478523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients.
    Takei M; Homma Y;
    Int J Urol; 2005 May; 12(5):456-64. PubMed ID: 15948744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of tolterodine for the treatment of overactive bladder in adults.
    Roberts RG; Garely AD; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S158-62. PubMed ID: 16161389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials.
    Nijman RJ; Borgstein NG; Ellsworth P; Djurhuus JC
    J Urol; 2005 Apr; 173(4):1334-9. PubMed ID: 15758796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trospium chloride for the treatment of overactive bladder with urge incontinence.
    Singh-Franco D; Machado C; Tuteja S; Zapantis A
    Clin Ther; 2005 May; 27(5):511-30. PubMed ID: 15978301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways.
    Kim Y; Yoshimura N; Masuda H; de Miguel F; Chancellor MB
    Urology; 2005 Feb; 65(2):238-42. PubMed ID: 15708029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study.
    Nijman RJ; Borgstein NG; Ellsworth P; Siggaard C
    Eur Urol; 2007 Nov; 52(5):1511-6. PubMed ID: 17574729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of tolterodine in children with neurogenic detrusor overactivity: relationship between dose and urodynamic response.
    Ellsworth PI; Borgstein NG; Nijman RJ; Reddy PP
    J Urol; 2005 Oct; 174(4 Pt 2):1647-51; discussion 1651. PubMed ID: 16148673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
    Kennelly MJ; Lemack GE; Foote JE; Trop CS
    Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia.
    Nitti VW; Dmochowski R; Appell RA; Wang JT; Bavendam T; Guan Z;
    BJU Int; 2006 Jun; 97(6):1262-6. PubMed ID: 16686723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Spasmex treatment of patients with hyperactive urinary bladder].
    Pushkar' DIu; Shchaveleva OB
    Urologiia; 2003; (4):46-9. PubMed ID: 12942728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
    Abrams P; Kaplan S; De Koning Gans HJ; Millard R
    J Urol; 2006 Mar; 175(3 Pt 1):999-1004; discussion 1004. PubMed ID: 16469601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.